AMA president Jack Resneck, Jr., MD, and David M. Pariser, MD, FAAD, a dermatologist in private practice, tell us their thoughts and experiences on the challenges patients face in accessing methotrexate.
Gregory M Marcus, MD, MAS, and Jeffrey J. Hsu, MD, PhD, discuss the effect of caffeine and energy supplements on risk for cardiovascular events.
In addition to the physical risks, experts anticipate a myriad of mental health ramifications stemming from the loss of abortion access and the associated economic and occupational repercussions.
Tamara Horwich, MD, Eugenia Gianos, MD, and Kenneth Fleisher, DDS, reflect on the link between cardiovascular disease and oral health.
Sandra Springer, MD, and Laura Marks, MD, PhD, highlight the need for a combined treatment approach for patients with drug-use associated infections.
A look into the growing number of cases of stress cardiomyopathy, also known as Takotsubo syndrome, that have been observed during the COVID-19 pandemic.
What are the most effective pharmacologic therapies recommended for treating patients with moderate to severe COVID-19? Drs Sarina Sahetya of Johns Hopkins University, Matthew Exline of Ohio State University, and Minjoung Go of Stanford University offer their perspectives.
Elizabeth Profita, MD, and Gerard J. Boyle, MD, FACC, discuss myocarditis in younger populations and how pediatric cardiologists should respond with treatment.
Compared with nonpharmacologic approaches, research consistently supports the benefits of medication for opioid use disorder, including fewer deaths, higher rates of sustained recovery, and greater cost-effectiveness.
Katy Leung, MD, provides insight into the existing sex and gender differences between men and women with axial spondyloarthritis.
